Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 15, 2026, 9:24 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 577–600 of 790 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Therapy for head and neck cancer Clear all
Completed Not applicable Interventional

Neurological Effects of Acupuncture to Prevent Radiation-induced Xerostomia

NCT02292368
View directory record Official record
Conditions
Head and Neck Cancer
Interventions
Questionnaires, Acupuncture, Electroencephalogram (EEG)
Behavioral · Procedure
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2022
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 1, 2022 · Synced Oct 15, 2026, 9:24 PM EDT
Completed Phase 1Phase 2 Interventional

Paclitaxel and Radiation Therapy Plus Chemoprotection With Amifostine in Treating Patients With Stage III or Stage IV Head and Neck Cancer

NCT00003193
View directory record Official record
Conditions
Head and Neck Cancer, Oral Complications
Interventions
amifostine trihydrate, paclitaxel, conventional surgery, radiation therapy
Drug · Procedure · Radiation
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2005
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 6, 2012 · Synced Oct 15, 2026, 9:24 PM EDT
Completed Not applicable Interventional Results available

Feasibility of IMRT Modulation to Account for Scattered Radiation From Dental Fillings in Head and Neck Cancer

NCT01576939
View directory record Official record
Conditions
Head and Neck Cancer
Interventions
Intensity Modulated Radiation Therapy
Radiation
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Jun 14, 2017 · Synced Oct 15, 2026, 9:24 PM EDT
Terminated Phase 2Phase 3 Interventional Results available

BEMPEG With Pembrolizumab vs Pembrolizumab Alone in Patients With Metastatic or Recurrent HNSCC (PROPEL-36)

NCT04969861
View directory record Official record
Conditions
Metastatic Head and Neck Cancer, Recurrent Head and Neck Cancer
Interventions
Bempegaldesleukin, Pembrolizumab
Drug
Lead sponsor
Nektar Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Jan 12, 2023 · Synced Oct 15, 2026, 9:24 PM EDT
Completed Phase 2 Interventional

PEG-interferon Alfa-2b in Treating Patients With Stage II, Stage III, or Stage IV Head and Neck Cancer That Can Be Removed By Surgery

NCT00276523
View directory record Official record
Conditions
Head and Neck Cancer
Interventions
PEG-interferon alfa-2b, Conventional surgery, Neoadjuvant therapy
Biological · Procedure
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 31, 2012 · Synced Oct 15, 2026, 9:24 PM EDT
Completed Phase 3 Interventional Results available

Radiation Therapy Cisplatin With or Without Fluorouracil Patients With Stage III or Stage IV Head and Neck Cancer

NCT00608205
View directory record Official record
Conditions
Head and Neck Cancer
Interventions
cisplatin, fluorouracil, radiation therapy
Drug · Radiation
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
69 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2016
U.S. locations
2
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 6, 2020 · Synced Oct 15, 2026, 9:24 PM EDT
Completed Not applicable Interventional

PRO-ACTIVE: Prophylactic Swallow Intervention for Patients Receiving Radiotherapy for Head and Neck Cancer

NCT03455608
View directory record Official record
Conditions
Dysphagia
Interventions
RE-ACTIVE, PRO-ACTIVE EAT, PRO-ACTIVE EAT + EXERCISE
Behavioral
Lead sponsor
University Health Network, Toronto
Other
Eligibility
18 Years and older
Enrollment
952 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
10
States / cities
Miami, Florida • Orlando, Florida • Baltimore, Maryland + 7 more
Source: ClinicalTrials.gov public record
Updated Dec 10, 2024 · Synced Oct 15, 2026, 9:24 PM EDT
Suspended Not applicable Interventional

Multispectral Optoacoustic Tomography in Head and Neck Squamous Cell Cancer

NCT06477003
View directory record Official record
Conditions
Head and Neck Squamous Cell Carcinoma
Interventions
Multispectral Optoacoustic Tomography, Temperature Measurement
Device · Procedure
Lead sponsor
University of Oklahoma
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Oklahoma City, Oklahoma
Source: ClinicalTrials.gov public record
Updated Aug 18, 2026 · Synced Oct 15, 2026, 9:24 PM EDT
Completed Phase 1 Interventional

Safety Study of Afatinib and Postoperative Radiation Therapy to Treat Head and Neck Cancer

NCT01783587
View directory record Official record
Conditions
Squamous Cell Carcinoma of the Head and Neck
Interventions
Afatinib, Docetaxel, Radiation Therapy
Drug · Radiation
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
3
States / cities
Boston, Massachusetts • New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 25, 2026 · Synced Oct 15, 2026, 9:24 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

A Safety, Tolerability and Efficacy Study of NC410 Plus Pembrolizumab in Participants With Advanced Unresectable or Metastatic Solid Tumors

NCT05572684
View directory record Official record
Conditions
Advanced or Metastatic Solid Tumors, Microsatellite Instability Low, Microsatellite Instability High, Microsatellite Stable, Ovarian Cancer, Gastric Cancer, Colo-rectal Cancer, Esophageal Cancer, Endometrial Cancer, Head Neck Cancer, Cervical Cancer, Lung Cancer
Interventions
NC410, pembrolizumab
Drug
Lead sponsor
NextCure, Inc.
Industry
Eligibility
18 Years and older
Enrollment
97 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
17
States / cities
Tucson, Arizona • Aurora, Colorado • Edgewood, Kentucky + 11 more
Source: ClinicalTrials.gov public record
Updated Aug 13, 2026 · Synced Oct 15, 2026, 9:24 PM EDT
Terminated Phase 2 Interventional

Cobiprostone for the Prevention of Oral Mucositis in Subjects With Head and Neck Cancer Receiving Concurrent Radiation and Chemotherapy

NCT02542215
View directory record Official record
Conditions
Oral Mucositis
Interventions
Cobiprostone, Placebo, Standard Care - Chemotherapy, Standard Care - Radiation
Drug · Radiation
Lead sponsor
Sucampo Pharma Americas, LLC
Industry
Eligibility
18 Years and older
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
76
States / cities
Birmingham, Alabama • Peoria, Arizona • Yuma, Arizona + 72 more
Source: ClinicalTrials.gov public record
Updated Dec 2, 2019 · Synced Oct 15, 2026, 9:24 PM EDT
Completed Phase 2 Interventional Results available

Respiratory-Swallow Training in Veterans With Oropharyngeal Cancer

NCT01032928
View directory record Official record
Conditions
Oropharyngeal Dysphagia, Oropharyngeal Cancer
Interventions
Respiratory-Swallow Phase training
Behavioral
Lead sponsor
US Department of Veterans Affairs
Federal
Eligibility
21 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Jan 1, 2015 · Synced Oct 15, 2026, 9:24 PM EDT
Recruiting Phase 1Phase 2 Interventional

A Study of DB-1310 in Advanced/Metastatic Solid Tumors

NCT05785741
View directory record Official record
Conditions
Advanced Solid Tumor
Interventions
DB-1310, Trastuzumab, Osimertinib, capecitabine
Drug
Lead sponsor
DualityBio Inc.
Industry
Eligibility
18 Years and older
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
15
States / cities
Sacramento, California • Santa Monica, California • Coral Gables, Florida + 12 more
Source: ClinicalTrials.gov public record
Updated Apr 6, 2026 · Synced Oct 15, 2026, 9:24 PM EDT
Withdrawn Not applicable Interventional

Endodontic-Restorative Pre-Radiation Therapy of Head and Neck Cancer Patients

NCT04996641
View directory record Official record
Conditions
Pulpitis - Irreversible, Caries, Head and Neck Cancer
Interventions
Root canal treatment and crown
Procedure
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 27, 2023 · Synced Oct 15, 2026, 9:24 PM EDT
Recruiting Not applicable Interventional

High-Resolution PET-CT Imaging for Surgical Margin Visualization

NCT06915454
View directory record Official record
Conditions
Cancer, Solid Malignant Tumors, SCC - Squamous Cell Carcinoma, HNSCC, HNSCC,Larynx, Pharynx and Oral Cavity
Interventions
Intra-op PET/CT Specimen Scanner
Device
Lead sponsor
Vanderbilt-Ingram Cancer Center
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated May 8, 2026 · Synced Oct 15, 2026, 9:24 PM EDT
Completed Phase 2 Interventional Results available

Irinotecan and Cisplatin in Treating Patients With Recurrent or Metastatic Head and Neck Cancer

NCT00639769
View directory record Official record
Conditions
Head and Neck Cancer
Interventions
cisplatin, irinotecan hydrochloride
Drug
Lead sponsor
Vanderbilt-Ingram Cancer Center
Other
Eligibility
18 Years and older
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2008
U.S. locations
8
States / cities
Macon, Georgia • Chattanooga, Tennessee • Jackson, Tennessee + 3 more
Source: ClinicalTrials.gov public record
Updated Sep 14, 2012 · Synced Oct 15, 2026, 9:24 PM EDT
Not yet recruiting Not applicable Interventional Accepts healthy volunteers

Peer Support Program for Improving Quality of Life Among Head and Neck Patients, Connecting Through Cancer Trial

NCT07664241
View directory record Official record
Conditions
Malignant Head and Neck Neoplasm
Interventions
Supportive Care, Survey Administration, Interview
Other
Lead sponsor
OHSU Knight Cancer Institute
Other
Eligibility
18 Years to 89 Years
Enrollment
56 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Jul 15, 2026 · Synced Oct 15, 2026, 9:24 PM EDT
Active, not recruiting Phase 2 Interventional

Cemiplimab in Treating Patients With Recurrent and Resectable Stage II-IV Head and Neck Cutaneous Squamous Cell Cancer Before Surgery

NCT03565783
View directory record Official record
Conditions
Recurrent Cutaneous Squamous Cell Carcinoma of the Head and Neck, Resectable Cutaneous Squamous Cell Carcinoma of the Head and Neck, Stage II Cutaneous Squamous Cell Carcinoma of the Head and Neck AJCC v8, Stage III Cutaneous Squamous Cell Carcinoma of the Head and Neck AJCC v8, Stage IV Cutaneous Squamous Cell Carcinoma of the Head and Neck AJCC v8
Interventions
Cemiplimab
Biological
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 16, 2026 · Synced Oct 15, 2026, 9:24 PM EDT
Completed Phase 1 Interventional

Carboplatin, Capecitabine, and Radiation Therapy in Treating Patients With Stage III or Stage IV Head and Neck Cancer

NCT00114153
View directory record Official record
Conditions
Head and Neck Cancer
Interventions
capecitabine, carboplatin, conventional surgery, radiation therapy
Drug · Procedure · Radiation
Lead sponsor
University of Virginia
Other
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2003
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Nov 26, 2009 · Synced Oct 15, 2026, 9:24 PM EDT
Active, not recruiting Phase 1Phase 2 Interventional

First-in-human Study of DB-1305/BNT325 for Advanced/Metastatic Solid Tumors

NCT05438329
View directory record Official record
Conditions
Advanced Solid Tumor
Interventions
DB-1305/BNT325, Pembrolizumab, BNT327
Drug · Combination Product
Lead sponsor
DualityBio Inc.
Industry
Eligibility
18 Years and older
Enrollment
1,123 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
42
States / cities
Bullhead City, Arizona • Cerritos, California • La Jolla, California + 34 more
Source: ClinicalTrials.gov public record
Updated May 12, 2026 · Synced Oct 15, 2026, 9:24 PM EDT
Terminated Phase 1 Interventional Results available

Adoptive Cell Transfer of Autologous Tumor Infiltrating Lymphocytes and High-Dose Interleukin 2 in Select Solid Tumors

NCT03991741
View directory record Official record
Conditions
Metastatic Melanoma, Locally Advanced Refractory/Recurrent Melanoma, Metastatic Head and Neck Cancer, Locally Advanced Refractory/Recurrent Head and Neck Cancer
Interventions
Autologous Tumor Infiltrating Lymphocytes, High-Dose Interleukin 2
Biological
Lead sponsor
Gregory Daniels
Other
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Jul 3, 2025 · Synced Oct 15, 2026, 9:24 PM EDT
Completed Phase 1 Interventional

Phase I of Biologics and Chemoradiation Therapy for Advanced Head and Neck Cancer

NCT00405405
View directory record Official record
Conditions
Head and Neck Cancer, Parotid Gland Cancer, Thyroid Gland Cancer, Melanoma, Stage IV Head and Neck Cancer
Interventions
Cisplatin, Docetaxel, Bevacizumab, Erlotinib, Radiotherapy
Drug · Radiation
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Other
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 6, 2025 · Synced Oct 15, 2026, 9:24 PM EDT
Recruiting Phase 3 Interventional

A Study of ASP-1929 Photoimmunotherapy in Combination With Pembrolizumab in First-line Treatment of Locoregional Recurrent Squamous Cell Carcinoma of the Head and Neck With No Distant Metastases

NCT06699212
View directory record Official record
Conditions
Recurrent Head and Neck Squamous Cell Carcinoma
Interventions
ASP-1929 Photoimmunotherapy, Pembrolizumab, Carboplatin, Cisplatin, 5-fluorouracil, Paclitaxel, Docetaxel
Combination Product · Biological · Drug
Lead sponsor
Rakuten Medical, Inc.
Industry
Eligibility
18 Years and older
Enrollment
412 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
8
States / cities
Duarte, California • Miami, Florida • Tampa, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Oct 15, 2025 · Synced Oct 15, 2026, 9:24 PM EDT
Completed Phase 2 Interventional

Study to Determine the Effects Treatment With Amlexanox 0.5% Oral Rinse Solution on Oral Mucositis Associated With Radiation Therapy for Cancer of the Head and Neck Region

NCT01083875
View directory record Official record
Conditions
Oral Mucositis
Interventions
amlexanox, Vehicle rinse
Drug
Lead sponsor
Access Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2001
U.S. locations
12
States / cities
Mobile, Alabama • Little Rock, Arkansas • Bakersfield, California + 9 more
Source: ClinicalTrials.gov public record
Updated Mar 18, 2010 · Synced Oct 15, 2026, 9:24 PM EDT